利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1709 条记录 (耗时 0.027 秒)

    CARRIER PROTEIN WITH SITE-DIRECTED MUTATION AND USE THEREOF IN PREPARATION OF VACCINE
    34.
    发明申请
    CARRIER PROTEIN WITH SITE-DIRECTED MUTATION AND USE THEREOF IN PREPARATION OF VACCINE 有权

    公开(公告)号：US20230111095A1

    公开(公告)日：2023-04-13

    申请号：US17769607

    申请日：2020-09-25

    申请人： Cansino Biologics Inc.

    发明人： Haomeng WANG ,  Qiaoling YAN ,  Shoubai CHAO ,  Huhua MAO ,  Tao ZHU

    IPC分类号： A61K39/385 ,  A61P31/04 ,  A61K39/09

    摘要： The present invention relates to a carrier protein with site-directed mutation and use thereof in preparation of a vaccine, wherein the carrier protein is selected from fusion proteins formed by one, two or more of diphtheria toxoid, a non-toxic mutant of diphtheria toxin, a bacterial outer membrane protein and a bacterially expressed protein, wherein an amino acid at at least one site on the carrier protein is mutated into an unnatural amino acid, and the unnatural amino acid contains an azido or alkynyl terminal group. In a mutual reaction process of the carrier protein with site-directed mutation of the present invention and a polysaccharide antigen, a covalent bond is formed, and meanwhile a formed conjugate is in a bead-string state, so that the carrier protein and the polysaccharide antigen can be effectively prevented from being excessively crosslinked. Further, particle size distribution of the conjugate is significantly uniform and controllable, which provides an effective means for improving quality of a polysaccharide-protein conjugate vaccine.

    Image processing of streptococcal infection in pharyngitis subjects
    37.
    发明授权
    Image processing of streptococcal infection in pharyngitis subjects 有权

    公开(公告)号：US11602312B2

    公开(公告)日：2023-03-14

    申请号：US17747495

    申请日：2022-05-18

    申请人： Light AI Inc.

    发明人： Sarbjit Sarkaria ,  Steven Rebiffe ,  Udit Gupta ,  Mahendran Maliapen ,  Peter Whitehead

    IPC分类号： A61B5/00 ,  A61K9/00 ,  G16H30/40 ,  G06K9/62 ,  G16H50/50 ,  A61K39/09

    摘要： A method for determining a disease state prediction, relating to a potential disease or medical condition of a subject, includes accessing a set of subject images, the subject images capturing a part of a subject's body, and accessing a set of clinical factors from the subject. The clinical factors are collected by a device or a medical practitioner substantially contemporaneously with the capture of the subject images. The subject images are inputted into an image model to generate disease metrics for disease prediction for the subject. The disease metrics generated by the image model and the clinical factors are inputted into a classifier to determine the disease state prediction, and the disease state prediction is returned.

    Protein antigens that provide protection against pneumococcal colonization and/or disease
    39.
    发明授权
    Protein antigens that provide protection against pneumococcal colonization and/or disease 有权

    公开(公告)号：US11576958B2

    公开(公告)日：2023-02-14

    申请号：US14766252

    申请日：2014-02-07

    申请人： CHILDREN'S MEDICAL CENTER CORPORATION

    发明人： Richard Malley ,  Yingjie Lu ,  Fan Zhang

    IPC分类号： A61K39/09 ,  C07K14/315 ,  A61K39/00

    摘要： The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumococcus immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a therapeutic immune response to an infected individual.